Former Board Member Files Intent to Sell $477K in Clene Inc. Shares Amid Going Concern Warning
CLNN has more than doubled off its 52-week low of $2.28.
Summary
Symbiosis II LLC, a former board member of Clene Inc., has filed a Form 144 indicating intent to sell 82,212 shares worth approximately $477,000, continuing a pattern of significant share dispositions.
Key Events · Ownership and Investor Activity · CLNN
-
Proposed Share Sale
Symbiosis II LLC, a former board member, intends to sell 82,212 common shares valued at approximately $477,000.
-
Continuation of Selling Pattern
This proposed sale follows over $1.3 million in share sales by the same entity in the past three months, indicating a sustained distribution.
-
Financial Distress Context
The selling occurs shortly after Clene Inc. disclosed "substantial doubt about its ability to continue as a going concern" in its recent 10-K filing.
Analysis · CLNN · Life Sciences
This Form 144 filing signals continued distribution by Symbiosis II LLC, a former board member, who has already sold over $1.3 million in shares in the past three months. The proposed sale of an additional $477,000 worth of shares is a substantial transaction for Clene Inc., representing approximately 0.7% of its market capitalization. This ongoing insider selling is particularly concerning given the company's recent 10-K filing, which disclosed "substantial doubt about its ability to continue as a going concern." While the company recently secured an oversubscribed financing, the persistent selling by a former insider, especially one with prior board insight, could be interpreted as a lack of confidence in the company's long-term prospects and adds to the negative sentiment surrounding its financial stability.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 34.9% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $5.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.5M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.